Share Email Print

Proceedings Paper

Targeted photolysis of melanoma cells by Alfa-Terthienyl derivative labeled antimelanoma monoclonal antibody
Author(s): Gabrio Roncucci; A. Di Stefano; P. Soldani; P. Neri; D. Neri
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Antibody targeted chemotherapy is a relatively new technique which involves the specifically carrier mediated delivery ofchemotherapeutic agents to tumors or other pathogens for the treatment of such deseases. Conjugation of antibodies with photosensitizers (PSs) can also lead to potential therapeutic agents which combine photodynaniic cytotoxicity with specific antibody binding. The antibody mediated delivery of a photosensitizer molecule and the target destruction upon irradiation by light followed by production of singlet oxigen or other radicals, results in a higher therapeutic ratio compared to the conventional photodynarnic therapy (PDT). In this study the naturally occurring PS Alphà-Terthienile (ATT) was chemically derivatized with an amino group specific reactive side arm and in order to exploit its toxicity as an effector function suitable for targeted photolysis, covalently conjugated to the 225.28S monoclonal antibody (inAb) specific for the high molecular weight melanoma associated antigen (HMW-MAA). The 225-28S-ATT conjugate prepared was then tested against the melanoma cell line Co1o38 in comparison with HT29 tumor cells, not recognized by 225-28S mAb, as negative control. The selective uptake of labelled niAb 22528S-ATF and the melanoma cells death following irradiation can be observed. In conclusion the 225-28S-ATT conjugate, as far as one can judge from the effect on cells grown in vitro, seems a good candidate as a model to test the antibody targeted photolysis of melanoma cells for developing specific antimelanoma therapeutic agents.

Paper Details

Date Published: 31 January 1996
PDF: 11 pages
Proc. SPIE 2625, Photochemotherapy: Photodynamic Therapy and Other Modalities, (31 January 1996); doi: 10.1117/12.230949
Show Author Affiliations
Gabrio Roncucci, Molteni Farmaceutici (Italy)
A. Di Stefano, Univ. de Siena (Italy)
P. Soldani, Univ. di Siena (Italy)
P. Neri, Univ. di Siena (Italy)
D. Neri, MCR Cambridge Ctr. for Protein Engineering (United Kingdom)

Published in SPIE Proceedings Vol. 2625:
Photochemotherapy: Photodynamic Therapy and Other Modalities
Benjamin Ehrenberg; Giulio Jori; Johan Moan, Editor(s)

© SPIE. Terms of Use
Back to Top